LUND, Sweden, Nov. 11, 2020 /PRNewswire/ -- The Nomination
Committee, which is to be appointed for the period until a new
Nomination Committee is appointed, shall consist of four members,
of which three will be appointed by the Company's three largest
shareholders in terms of voting, and the fourth shall be the
Chairman of the Board. In the event that the Chairman of the Board
is one of the three largest shareholders, he shall, in his/her
capacity as shareholder, make his seat available and the next
shareholder shall be offered the right to appoint a member to the
Nomination Committee. The Chairman of the Board shall, as soon as
reasonably practicable after the end of the third quarter, contact
the three largest shareholders registered in the share register
kept by Euroclear Sweden AB at this time in an appropriate manner
and request them to, within a reasonable time, may not exceed 30
days, in writing to the Nomination Committee name the person the
shareholder wishes to appoint as a member of the Nomination
Committee. If one of the three largest shareholders does not wish
to exercise his right to appoint a member of the Nomination
Committee, the next shareholder shall in turn be offered the right
to appoint a member of the Nomination Committee. In the event that
several shareholders waive their right to appoint members of the
Nomination Committee, the Chairman of the Board shall not have to
contact more than eight shareholders, unless it is necessary to
convene a Nomination Committee consisting of at least three
members.
Unless otherwise agreed between the members, the member
appointed by the largest shareholder in terms of number of votes
shall be appointed chairman of the nomination committee. The
Chairman of the Board or another Board member shall never be the
Chairman of the Nomination Committee.
Based on the above, the Nomination Committee for the 2021 Annual
General Meeting has been determined to consist of the following
persons who together represent approximately 25 percent of the
number of shares and votes in the company as of September 30, 2020:
- Bo Lundgren, representing
Robur
- Carl Borrebaeck representing Carl Borrebaeck, Chairman of the
Board
- Peter Lindvall representing
Mikael Löfman; and
- Astrid Samuelsson, representing
Handelsbanken
The Nomination Committee's proposal will be presented in the
notice convening the Annual General Meeting 2020 and at the
company's website, www.immunovia.com.
Shareholders who wish to submit proposals to the Nomination
Committee are welcome to contact the Nomination Committee at the
company's address. In order for the Nomination Committee to be able
to consider a proposal, the proposal must have been received in
good time before the Annual General Meeting, but no later than
31 January 2021.
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/nomination-committee-appointed-for-the-2021-annual-general-meeting-of-immunovia-ab--publ-,c3234834
The following files are available for download:
https://mb.cision.com/Main/13121/3234834/1333337.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/nomination-committee-appointed-for-the-2021-annual-general-meeting-of-immunovia-ab-publ-301170518.html
SOURCE Immunovia AB